Alto Neuroscience Appoints Andrew Dreyfus to Its Board of Directors
Alto Neuroscience today announced the appointment of Andrew Dreyfus, former president and CEO of BCBSMA, to the company’s board of directors as an independent board member.
- Alto Neuroscience today announced the appointment of Andrew Dreyfus, former president and CEO of BCBSMA, to the company’s board of directors as an independent board member.
- Mr. Dreyfus brings decades of experience in health insurance and healthcare reform to support the advancement of Alto’s late-stage precision psychiatry pipeline.
- “His unique experience at the intersection of insurance and policy will be invaluable as we continue to build our clinical development strategy.
- “I am honored to join the Alto board of directors at such a pivotal stage in the company’s development, coinciding with a time of continued unmet need in our country’s mental healthcare,” added Andrew Dreyfus.